Lupin declines after USFDA concludes inspection with two observations at Ankleshwar facility

09 Mar 2026 Evaluate

Lupin is currently trading at Rs. 2288.50, down by 55.95 points or 2.39% from its previous closing of Rs. 2344.45 on the BSE.

The scrip opened at Rs. 2297.40 and has touched a high and low of Rs. 2318.45 and Rs. 2283.00 respectively. So far 19622 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 2368.00 on 06-Mar-2026 and a 52 week low of Rs. 1774.00 on 07-Apr-2025.

Last one week high and low of the scrip stood at Rs. 2368.00 and Rs. 2256.05 respectively. The current market cap of the company is Rs. 105442.16 crore.

The promoters holding in the company stood at 46.89%, while Institutions and Non-Institutions held 47.07% and 6.03% respectively.

US Food and Drug Administration (USFDA) has concluded an inspection at Lupin’s manufacturing facility at Ankleshwar, India. The Inspection was conducted from March 02, 2026 to March 07, 2026 and closed with the issuance of a Form-483 with two observations. The company will address the observations and respond to the USFDA within the stipulated timeframe.

Lupin is an innovation led transnational pharmaceutical company producing, developing and marketing a wide range of branded and generic formulations, biotechnology products and active pharmaceutical ingredients (APIs) globally.

Lupin Share Price

2340.75 39.05 (1.70%)
10-Mar-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1813.00
Dr. Reddys Lab 1313.90
Cipla 1333.10
Zydus Lifesciences 922.90
Lupin 2340.75
View more..
Register Now to get our Free Newsletter & much more!

© 2026 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×